Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.16Last Year’s EPS
0.1Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Aurinia Pharmaceuticals reported strong financial performance with significant revenue and net product sales growth, improved cash flow, increased guidance, and successful clinical trial results. However, there were decreases in cash, cash equivalents, and investments due to share repurchases.Company Guidance
Strong Revenue Growth
Total revenue for the 3 and 6 months ended June 30, 2025, was $70 million and $132.5 million, up 22% and 23%, respectively, from the same periods in 2024.
Increased Net Product Sales of LUPKYNIS
Net product sales for LUPKYNIS were $66.6 million and $126.5 million for the 3 and 6 months ended June 30, 2025, representing increases of 21% and 23%, respectively, from the same periods in 2024.
Positive Cash Flow from Operations
Cash flow generated from operations was $45.5 million for the 6 months ended June 30, 2025, compared to a negative $2.8 million in the same period of 2024.
Raised Full Year 2025 Revenue Guidance
Full year 2025 total revenue guidance was increased from $250-260 million to $260-270 million, and net product sales guidance was raised from $240-250 million to $250-260 million.
Successful Aritinercept Phase I Study
Reported positive results from the aritinercept Phase I single ascending dose study, with plans to initiate further clinical studies in the second half of the year.
Improved Gross Margin
Gross margin for the 3 and 6 months ended June 30, 2025, was 90% and 88%, respectively, compared to 84% and 85% in the same periods in 2024.
Reduced Operating Expenses
Total operating expenses decreased to $49.9 million and $90.5 million for the 3 and 6 months ended June 30, 2025, from $58.7 million and $122.3 million in the comparable periods of 2024.
Net Income Increase
Net income for the 3 and 6 months ended June 30, 2025, was $21.5 million and $44.9 million, respectively, compared to $722,000 and a net loss of $10 million in the same periods of 2024.
AUPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AUPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 31, 2025 | $9.05 | $9.24 | +2.10% |
May 12, 2025 | $8.00 | $8.12 | +1.50% |
Feb 27, 2025 | $7.95 | $7.55 | -5.03% |
Nov 07, 2024 | $7.52 | $8.34 | +10.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aurinia Pharmaceuticals (AUPH) report earnings?
Aurinia Pharmaceuticals (AUPH) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is Aurinia Pharmaceuticals (AUPH) earnings time?
Aurinia Pharmaceuticals (AUPH) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AUPH EPS forecast?
AUPH EPS forecast for the fiscal quarter 2025 (Q3) is 0.16.
